Andrew Callos Sells 3,341 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) Stock

Cytokinetics, Incorporated (NASDAQ:CYTK) EVP Andrew Callos sold 3,341 shares of the company’s stock in a transaction that occurred on Thursday, March 6th. The shares were sold at an average price of $43.27, for a total value of $144,565.07. Following the sale, the executive vice president now owns 64,434 shares in the company, valued at $2,788,059.18. The trade was a 4.93 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Cytokinetics Stock Performance

Shares of CYTK opened at $43.43 on Friday. The company has a debt-to-equity ratio of 5.93, a quick ratio of 9.28 and a current ratio of 9.28. The firm has a market capitalization of $5.14 billion, a P/E ratio of -8.07 and a beta of 0.95. The stock has a 50 day moving average price of $46.80 and a two-hundred day moving average price of $50.92. Cytokinetics, Incorporated has a 52 week low of $40.53 and a 52 week high of $75.71.

Cytokinetics (NASDAQ:CYTK) last posted its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($1.26) earnings per share for the quarter, topping the consensus estimate of ($1.29) by $0.03. The business had revenue of $16.93 million during the quarter, compared to analysts’ expectations of $14.26 million. Equities analysts forecast that Cytokinetics, Incorporated will post -5.24 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have commented on CYTK. HC Wainwright restated a “buy” rating and set a $120.00 price target on shares of Cytokinetics in a research report on Friday, February 28th. Citigroup initiated coverage on shares of Cytokinetics in a report on Friday, February 7th. They set a “buy” rating and a $86.00 price objective for the company. Morgan Stanley raised shares of Cytokinetics from an “equal weight” rating to an “overweight” rating and cut their price objective for the company from $70.00 to $67.00 in a research report on Thursday, February 13th. Mizuho raised their price target on shares of Cytokinetics from $99.00 to $103.00 and gave the stock an “outperform” rating in a research note on Thursday, November 21st. Finally, Needham & Company LLC restated a “buy” rating and issued a $72.00 price target on shares of Cytokinetics in a research report on Thursday, February 6th. Two investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $82.00.

Institutional Investors Weigh In On Cytokinetics

A number of hedge funds have recently modified their holdings of the stock. GF Fund Management CO. LTD. purchased a new position in Cytokinetics during the 4th quarter valued at about $117,000. Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. bought a new stake in Cytokinetics during the 4th quarter worth approximately $15,483,000. Vestal Point Capital LP grew its position in shares of Cytokinetics by 56.7% during the 4th quarter. Vestal Point Capital LP now owns 2,350,000 shares of the biopharmaceutical company’s stock valued at $110,544,000 after purchasing an additional 850,000 shares in the last quarter. Two Sigma Advisers LP boosted its stake in Cytokinetics by 5.4% during the fourth quarter. Two Sigma Advisers LP now owns 226,400 shares of the biopharmaceutical company’s stock valued at $10,650,000 after buying an additional 11,700 shares during the period. Finally, Teza Capital Management LLC purchased a new position in Cytokinetics during the fourth quarter worth about $446,000.

About Cytokinetics

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.